New EDCTP call: development of novel drugs for antimicrobial resistance
The European & Developing Countries Clinical Trials Partnership (EDCTP) funds clinical research to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics. Mainly focussed on HIV/AIDS, tuberculosis and malaria as well as other poverty-related infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials. The EDCTP2 programme is supported under Horizon 2020, the European Union’s Framework Programme for Research & Innovation.
Background of this call
Antimicrobials are increasingly becoming ineffective. Since pathogens can also develop resistance to multiple agents, multi-drug resistant infections emerge and spread that are very hard to control. The WHO has established a list of antibiotic-resistant priority pathogens. In addition to developing new or improved antimicrobials, an effective system to diagnose, detect, collect and integrate information about antimicrobial resistance (AMR) on a large scale is desperately needed.
Scope of the call
Within this call, clinical trials (Phase I-IV) to be conducted in sub-Saharan Africa are funded. These have to be aimed at developing new or improved medicinal products (drugs and vaccines) or combinations thereof against specific pathogens. More specifically, these are pathogens from the WHO priority list that also fall within the scope of the EDCTP2 programme, being Campylobacter, Salmonella, Streptococcus pneumoniae, and Mycobacterium tuberculosis.
Eligibility and available budget
- A proposal is only eligible if it consists of at least three legal entities.
- Two of the legal entities shall be established in two different Participating States (European Partner States) and one of the legal entities must be established in a sub-Saharan African country. All three legal entities must be independent of each other.
- ‘Sole participants’ formed by several legal entities (e.g. European Research Infrastructure Consortia, European Groupings of Territorial Cooperation, central purchasing bodies) are eligible if the above-mentioned minimum conditions are satisfied by the legal entities forming together the sole participant.
- Project duration is 36 to 60 months
- Deadline: 7 November 2019
- Funding level: 100% of eligible costs
- Call budget: € 18 million, 2-4 projects are expected to be funded. This means that proposal budgets can be in the range of € 4.5 -9 million
Become an EDCTP expert!
In case you are working in this field but do not currently have a project in mind, consider sharing your expertise on the topic as an expert. EDCTP relies on experts to ensure that only proposals of the highest quality are selected for funding.
Experts are external and independent to EDCTP and, in performing their evaluation(s), are working in a personal capacity rather than as a representative of any organisation or scientific community. If you become an expert, you will see the process of EDCTP from the inside.
This call is in line with the European Commission goals – since 2001 – to tackle AMR on a global scale and collaboratively. Most recent is the 2017 commitment “A European One Health Action Plan against Antimicrobial Resistance (AMR)”. This policy follows on from the 2011 Commission action plan, notable for its One Health approach, addressing AMR in both humans and animals. As part of developing and actively leading the global research agenda on AMR, the Commission is
- supporting the establishment of a virtual research institute under the Joint Programming Initiative on Antimicrobial resistance (JPIAMR);
- developing collaborative research with Sub-Saharan Africa by promoting cooperation with EDCTP;
- fostering international research collaboration on AMR in the animal health sector in the STARIDAZ International Research Consortium.
Curious to discover whether your research activities are in line with the call requirements? The specialists at Hezelburcht are experienced in developing and writing these types of applications. We look forward to supporting and advising you in your grant funding endeavours. Please contact us for more information!